P014 Diagnosis and Treatment Experience of 101 Patients with Advanced NSCLC Complicated with Chronic Obstructive Pulmonary Disease

To investigate the clinical characteristics of 101 patients with advanced non-small cell lung cancer (NSCLC) complicated with chronic obstructive pulmonary disease (COPD) and analyzing the interaction between treatment of lung cancer and COPD, putting forward the treatment strategy of "simultaneous treatment of cancer and lung itself." The clinical data of 101 patients with NSCLC complicated with COPD on January 1, 2015 to December 31, 2017 in The First Affiliated Hospital of Guangzhou Medical University were analyzed retrospectively, including age, sex, smoking history, clinical symptoms, pathological type, classification, lung function and treatment. The patients were divided into COPD treatment group and control group according to whether the patients received treatment for COPD. Then compare the therapeutic effect of the two groups. There were no significant differences in the disease control rate(DCR) and objective response rate (ORR) of COPD treatment group with control group (p＞0.05),while the period of first-line chemotherapy treatments in COPD treatment group were more than that of control group (4.8vs.3.8,p<0.05), and patients in COPD treatment group are more likely to receive second-line treatment (95.7%vs.75.0%,p<0.05). Progression-free surival (PFS) of COPD treatment group were significantly higher than control group(6.0 months vs.3.5 months, p<0.05),and Overall survival(OS) of COPD treatment group were significantly higher than control group(18.0 months vs.6.0 months,p<0.05). 1. COPD combined with advanced NSCLC occurs in male smokers more. The performance status (PS) score of majority range from 1 to 3. 2. There were no significant differences in the short-term therapeutic effect of two group, while the period of first-line chemotherapy treatments, OS and PFS of patients which regularly receive anti-COPD therapy were significantly higher than control group. 3. Patients in regular COPD treatment group are more likely to receive second-line chemotherapy.